

AAK1 Inhibition for the Treatment of Neuropathic Pain: Identification and Evaluation of Novel Candidates

CIMPLRX Co. Ltd.



NEUROLOGY	Candidate
Product Type	Small molecules
Indication	Neuropathic pain
Target	AAK1 (Adaptor-related protein complex 2-Associated Kinase 1)
MoA(Mechanism of Action)	AAK1 inhibition
Competitiveness	<ul style="list-style-type: none"> • Potent AAK1 inhibition with greater kinase selectivity compared to LX9211. • Improved CNS exposure supported by higher brain/plasma ratio and unbound brain levels compared to LX9211. • Lower hERG inhibition risk compared to LX9211.
Development Stage	Candidate
Route of Administration	Oral

Any unauthorized distribution or reproduction of this material is strictly prohibited.